FLOW with Peter Rossing
FLOW was the first randomised controlled trial to evaluate an GLP-1 receptor agonist (RA) in patients
living with type 2 diabetes and chronic kidney disease, and it was stopped early due to efficacy.
In this Expert Insights episode, FLOW steering group member Peter Rossing presents key results of
the study and also discusses open questions like: Will these effects translate to other incretin-based
therapies? And: Will patients without type 2 diabetes benefit as well?